NYSE:MD - MEDNAX Stock Price, Forecast & News

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

MEDNAX Inc (NYSE:MD) announced its quarterly earnings data on Thursday, February, 20th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.83 by $0.08. The business had revenue of $905.38 million for the quarter, compared to analysts' expectations of $900.85 million. MEDNAX had a positive return on equity of 12.22% and a negative net margin of 42.63%. The firm's quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.92 EPS. View MEDNAX's Earnings History.

MEDNAX is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for MEDNAX.

MEDNAX updated its first quarter earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of $0.55 to $0.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.63.

11 brokers have issued 12-month price objectives for MEDNAX's stock. Their forecasts range from $18.00 to $34.00. On average, they expect MEDNAX's stock price to reach $26.91 in the next twelve months. This suggests a possible upside of 34.6% from the stock's current price. View Analyst Price Targets for MEDNAX.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MEDNAX.

Media headlines about MD stock have been trending positive on Monday, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. MEDNAX earned a daily sentiment score of 2.6 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for MEDNAX.

Some companies that are related to MEDNAX include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), BioScrip (BIOS), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include Gilead Sciences (GILD), AbbVie (ABBV), Dominion Energy (D), Pfizer (PFE), Exxon Mobil (XOM), CVS Health (CVS), Chevron (CVX), Walt Disney (DIS), General Electric (GE) and AT&T (T).

MEDNAX's stock is owned by many different of institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (6.35%), P2 Capital Partners LLC (4.63%), State Street Corp (2.59%), FMR LLC (2.02%), LSV Asset Management (1.54%) and Prudential Financial Inc. (1.52%). Company insiders that own MEDNAX stock include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt, Michael Fernandez and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.

MD stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, FMR LLC, Panagora Asset Management Inc., State Street Corp, Goldman Sachs Group Inc., Man Group plc, AlphaCrest Capital Management LLC and Stone Ridge Asset Management LLC. Company insiders that have sold MEDNAX company stock in the last year include David A Clark, Dominic J Andreano, Joseph M Calabro and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.

MD stock was acquired by a variety of institutional investors in the last quarter, including P2 Capital Partners LLC, Great Lakes Advisors LLC, LSV Asset Management, Renaissance Technologies LLC, Bank of New York Mellon Corp, William Blair Investment Management LLC, Schroder Investment Management Group and Mackay Shields LLC. View Insider Buying and Selling for MEDNAX.

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MD stock can currently be purchased for approximately $19.99.

MEDNAX has a market capitalization of $1.69 billion and generates $3.51 billion in revenue each year. The company earns $268.62 million in net income (profit) each year or $3.14 on an earnings per share basis. MEDNAX employs 7,625 workers across the globe.View Additional Information About MEDNAX.

The official website for MEDNAX is http://www.mednax.com/.

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]